Calyx, a provider of Medical Imaging, eClinical, and Regulatory solutions and services to solve complex challenges in clinical research, has launched as an independent company following the strategic separation of the Parexel Informatics business from Parexel International.
“Today our industry needs to move at a 21st century pace and Calyx, as an independent company, is focused on enabling global biopharmaceutical customers and clinical research organizations (CROs) to leverage technology solutions and services in the pursuit of cures,” said Gavin Nichols, Chief Executive Officer at Calyx.
Calyx will remain privately held by the same ownership group that has owned and invested in Parexel since 2017.
